Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1 13Phase 3 9Phase 1/2 5Phase 4 4Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Glioma 2Uterine Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Breast Neoplasms 1

Interventions

olaparib 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4fludarabine 3X-Rays 2Taxes 2Platinum 2Paclitaxel 2Oncolytic Virotherapy 2Letrozole 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorodeoxyglucose F18 2Doxorubicin 2Cytoreduction Surgical Procedures 2Cisplatin 2Carboplatin 2Aspirin 21,2-diaminocyclohexaneplatinum II citrate 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1pertuzumab 1pembrolizumab 1palbociclib 1niraparib 1montelukast 1gallium 68 PSMA-11 1eribulin 1entrectinib 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ovarian Neoplasms × niraparib × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡